Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients

Liver Transplantation

Volumn 15, Issue 11, 2009, Pages 1564-1569

  Bucuvalas, John C ^a   Anand, Ravinder ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TACROLIMUS;

ADOLESCENT; ARTICLE; BILE DUCT ATRESIA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; PRIORITY JOURNAL; RETRANSPLANTATION; RISK REDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INCIDENCE; INFANT; KAPLAN-MEIERS ESTIMATE; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MULTIVARIATE ANALYSIS; REGISTRIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 72949123203     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21843     Document Type: Article

References (20)

1. Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl 2005;11:1469-1480. (Pubitemid 43072623)
2. Bierling P, Godeau B. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Hum Immunol 2005;66:387-394. (Pubitemid 40615794)
3. Clynes, R. Immune complexes as therapy for autoimmunity. J Clin Invest 2005;115:25-27.
4. Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods Mol Med 2005;109:403-408.
5. Peterlana D, Puccetti A, Simeoni S, Tinazzi E, Corrocher R, Lunardi C. Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 2005;24:18-21. (Pubitemid 40214795)
6. Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005;66:395-402. (Pubitemid 40615795)
7. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998;66:800-805. (Pubitemid 28460117)
8. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256-3262. (Pubitemid 39578859)
9. Jordan SC, Vo A, Bunnapradist S, Toyoda M, Peng A, Puliyanda D, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in livingdonor and cadaver recipients. Transplantation 2003;76:631-636. (Pubitemid 37071992)
10. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006;6:459-466. (Pubitemid 43382131)
11. Sivasai KS, Mohanakumar T, Phelan D, Martin S, Anstey ME, Brennan DC. Cytomegalovirus immune globulin intravenous (human) administration modulates immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 2000;119:559-565. (Pubitemid 30146355)
12. Bucuvalas JC, Alonso E. Outcome after liver transplantation: more than just survival rates. Liver Transpl 2005;11:7-9. (Pubitemid 40124436)
13. Bucuvalas JC, Campbell KM, Cole CR, Guthery SL. Outcomes after liver transplantation: keep the end in mind. J Pediatr Gastroenterol Nutr 2006;43(suppl 1):S41-S48. (Pubitemid 44014977)
14. Nascimbene A, Iannacone M, Brando B, De Gasperi A. Acute thrombocytopenia after liver transplant: role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol 2007;47:651-657. (Pubitemid 47503430)
15. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 1997;11(pt 1):432-437.
16. Kwekkeboom J, Tha-In T, Tra WM, Hop W, Boor PP, Mancham S, et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005;5:2393-2402. (Pubitemid 43919422)
17. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003;101:758-765. (Pubitemid 36077604)
18. Bayry J, Lacroix-Desmazes S, Delignat S, Mouthon L, Weill B, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:3497-3502. (Pubitemid 37531915)
19. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003;24(suppl 4):S217-S221. (Pubitemid 37304326)
20. Tha-In T, Metselaar HJ, Tilanus HW, Boor PP, Mancham S, Kuipers EJ, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006;81:1725-1734. (Pubitemid 43948307)